Trial Profile
Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer - A Collaborative Study of NRG Oncology and KROG
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer; Brain metastases; Male breast cancer
- Focus Therapeutic Use
- 28 Jun 2022 Status changed from active, no longer recruiting to completed.
- 13 Sep 2019 Planned primary completion date changed from 31 Aug 2019 to 31 Mar 2020.
- 13 Sep 2019 Status changed from recruiting to active, no longer recruiting.